DXCM · Dexcom Inc
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 13, 2022; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP gross profit non-GAAP | $838.5M | second quarter of 2026 | — |
GAAP → non-GAAP reconciliationGAAP GAAP gross profit 830M
+8.5M Amortization of intangible assets (1)
= Non-GAAP gross profit 838.5M
|
|||
| Non-GAAP operating income non-GAAP | $328.3M | second quarter of 2026 | — |
GAAP → non-GAAP reconciliationGAAP GAAP operating income 318.3M
+9.4M Amortization of intangible assets (1)
+0.6M Business transition and other significant items (2)
+0M Intellectual property litigation costs (3)
= Non-GAAP operating income 328.3M
|
|||
| Adjusted EBITDA non-GAAP | $1.35B | Full Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DXCM
this stock
Dexcom Inc
|
$33.87B | +35.2% | +60.2% | 35.6 | 4.6% |
|
ABT
Abbott Laboratories
|
$193.78B | -11.2% | +5.7% | 31.2 | 1.3% |
|
SYK
Stryker Corp
|
$130.11B | -3.5% | +11.2% | 35.2 | 2.2% |
|
MDT
Medtronic plc
|
$116.83B | -5.0% | +8.4% | 24.5 | 1.4% |
|
BSX
Boston Scientific Corp
|
$75.11B | -45.6% | +12.5% | 21.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jun 13, 2022; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DXCM | +5.9% | +17.1% | +22.5% | +7.6% | +35.2% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +5.5% | +12.6% | +8.7% | +3.6% | +21.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.